Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

MUC1 glycopeptide epitopes predicted by computational glycomics.

Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D.

Int J Oncol. 2012 Dec;41(6):1977-84. doi: 10.3892/ijo.2012.1645.

2.

Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Qu J, Yu H, Li F, Zhang C, Trad A, Brooks C, Zhang B, Gong T, Guo Z, Li Y, Ragupathi G, Lou Y, Hwu P, Huang W, Zhou D.

Int J Oncol. 2016 Feb;48(2):587-94. doi: 10.3892/ijo.2015.3302.

3.

Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.

Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ.

Biol Chem. 2009 Jul;390(7):611-8. doi: 10.1515/BC.2009.070.

4.

Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.

Tarp MA, Sørensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H.

Glycobiology. 2007 Feb;17(2):197-209.

PMID:
17050588
5.

Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.

Spencer DI, Missailidis S, Denton G, Murray A, Brady K, Matteis CI, Searle MS, Tendler SJ, Price MR.

Biospectroscopy. 1999;5(2):79-91.

PMID:
10217327
6.

An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.

Ohyabu N, Hinou H, Matsushita T, Izumi R, Shimizu H, Kawamoto K, Numata Y, Togame H, Takemoto H, Kondo H, Nishimura S.

J Am Chem Soc. 2009 Dec 2;131(47):17102-9. doi: 10.1021/ja903361f.

PMID:
19899793
7.
8.

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H.

Glycobiology. 2006 Feb;16(2):96-107.

PMID:
16207894
9.

Fast epitope mapping for the anti-MUC1 monoclonal antibody by combining a one-bead-one-glycopeptide library and a microarray platform.

Garcia-Martin F, Matsushita T, Hinou H, Nishimura S.

Chemistry. 2014 Nov 24;20(48):15891-902. doi: 10.1002/chem.201403239.

PMID:
25303614
10.

Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.

Sarkar S, Salyer AC, Wall KA, Sucheck SJ.

Bioconjug Chem. 2013 Mar 20;24(3):363-75. doi: 10.1021/bc300422a.

11.

Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.

Liu X, Sejbal J, Kotovych G, Koganty RR, Reddish MA, Jackson L, Gandhi SS, Mendonca AJ, Longenecker BM.

Glycoconj J. 1995 Oct;12(5):607-17.

PMID:
8595249
12.

Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.

Karsten U, Diotel C, Klich G, Paulsen H, Goletz S, Müller S, Hanisch FG.

Cancer Res. 1998 Jun 15;58(12):2541-9.

13.

Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.

Hanisch FG, Ninkovic T.

Curr Protein Pept Sci. 2006 Aug;7(4):307-15. Review.

PMID:
16918445
14.

Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).

Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S.

Glycobiology. 2004 Aug;14(8):681-92.

PMID:
15115750
15.

A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.

Matsushita T, Takada W, Igarashi K, Naruchi K, Miyoshi R, Garcia-Martin F, Amano M, Hinou H, Nishimura S.

Biochim Biophys Acta. 2014 Mar;1840(3):1105-16. doi: 10.1016/j.bbagen.2013.11.009.

16.

Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.

Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J.

Tumour Biol. 2000 Jul-Aug;21(4):197-210.

PMID:
10867613
17.

Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Abdel-Aal AB, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ.

Chembiochem. 2014 Jul 7;15(10):1508-13. doi: 10.1002/cbic.201402077.

18.
19.

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.

Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG.

Mol Immunol. 2009 Nov;47(1):131-40. doi: 10.1016/j.molimm.2008.09.032.

20.

Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.

Matsushita T, Ohyabu N, Fujitani N, Naruchi K, Shimizu H, Hinou H, Nishimura S.

Biochemistry. 2013 Jan 15;52(2):402-14. doi: 10.1021/bi3013142.

PMID:
23259747

Supplemental Content

Support Center